Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis Source: Virtual Congress 2020 – Tuberculosis: part 1 Year: 2020
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018 Year: 2018
Comparison of adverse effects in tuberculosis patients over 80 years of age with and without pyrazinamide treatment Source: International Congress 2017 – Human susceptibility to tuberculosis Year: 2017
Empirical treatment for tuberculosis: survey of cases treated over a period of two years Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis Source: Eur Respir J, 55 (3) 1901967; 10.1183/13993003.01967-2019 Year: 2020
Evaluation of drug resistance of patients with tuberculosis over a period of thirty years Source: Eur Respir J 2002; 20: Suppl. 38, 549s Year: 2002
Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update Source: Eur Respir J, 57 (5) 2002483; 10.1183/13993003.02483-2020 Year: 2021
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines – a preliminary report Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Efficacy of isoniazid preventive therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders-a retrospective cohort study in Taiwan Source: International Congress 2017 – Migrants and screening Year: 2017
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013
Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark Source: Eur Respir J 2014; 44: 540-543 Year: 2014